These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32163814)

  • 1. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
    Sarkar R; Banerjee S; Amin SA; Adhikari N; Jha T
    Eur J Med Chem; 2020 Apr; 192():112171. PubMed ID: 32163814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
    Adhikari N; Jha T; Ghosh B
    J Med Chem; 2021 Jul; 64(13):8827-8869. PubMed ID: 34161101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.
    Cao F; Zwinderman MRH; Dekker FJ
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29498635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
    Adhikari N; Amin SA; Trivedi P; Jha T; Ghosh B
    Eur J Med Chem; 2018 Sep; 157():1127-1142. PubMed ID: 30179749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
    Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.
    Amin SA; Adhikari N; Kotagiri S; Jha T; Ghosh B
    Eur J Med Chem; 2019 Mar; 166():369-380. PubMed ID: 30735902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of selective histone deacetylase 3 inhibition.
    Zhang L; Chen Y; Jiang Q; Song W; Zhang L
    Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects.
    Trivedi P; Adhikari N; Amin SA; Jha T; Ghosh B
    Eur J Pharm Sci; 2018 Nov; 124():165-181. PubMed ID: 30171982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
    Hsieh HY; Chuang HC; Shen FH; Detroja K; Hsin LW; Chen CS
    Eur J Med Chem; 2017 Nov; 140():42-51. PubMed ID: 28923385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors.
    Zhang L; Chen Y; Li F; Zhang L; Feng J; Zhang L
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1918-1927. PubMed ID: 35833370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors.
    Hu H; Xia J; Wang D; Wang XS; Wu S
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
    Gediya P; Parikh PK; Vyas VK; Ghate MD
    Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
    Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
    Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia.
    Liu E; Chen Y; Qin M; Yue K; Sun S; Jiang Y; Li X
    Eur J Med Chem; 2024 Oct; 276():116663. PubMed ID: 39047608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
    Sangwan R; Rajan R; Mandal PK
    Eur J Med Chem; 2018 Oct; 158():620-706. PubMed ID: 30245394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
    Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
    Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring different classification-dependent QSAR modelling strategies for HDAC3 inhibitors in search of meaningful structural contributors.
    Jha T; Jana R; Banerjee S; Baidya SK; Amin SA; Gayen S; Ghosh B; Adhikari N
    SAR QSAR Environ Res; 2024 May; 35(5):367-389. PubMed ID: 38757181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.